Evidence map›Paper›PMID 27769055›Full record

ArticleOncotarget2016

Progesterone potentiates the growth inhibitory effects of calcitriol in endometrial cancer via suppression of CYP24A1.

Amber A Bokhari, Laura R Lee, Dewayne Raboteau, Jane Turbov, Isabel V Rodriguez, John Wesley Pike, Chad A Hamilton, George Larry Maxwell, Gustavo C Rodriguez, Viqar Syed

RetractedOpen access · diamondAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Observational
  5. Article
  6. Knockdown of CYP24A1 Aggravates 1α,25(OH)Frontiers in oncology · 2020
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Amber A BokhariDepartment of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Laura R LeeDepartment of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Dewayne RaboteauDepartment of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Jane TurbovDivision of Gynecologic Oncology, North Shore University Health System, University of Chicago, Evanston, IL, USA.
Isabel V RodriguezDivision of Gynecologic Oncology, North Shore University Health System, University of Chicago, Evanston, IL, USA.
John Wesley PikeDepartment of Biochemistry, University of Wisconsin, Madison, WI, USA.
Chad A HamiltonDepartment of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
George Larry MaxwellJohn P. Murtha Cancer Center at Water Reed National Military Medical Center, Bethesda, MD, USA.
Gustavo C RodriguezDivision of Gynecologic Oncology, North Shore University Health System, University of Chicago, Evanston, IL, USA.
Viqar SyedDepartment of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Uniformed Services University of the Health Sciences · USWalter Reed National Military Medical Center · USNorthShore University HealthSystem · USUniversity of Chicago · USUniversity of Wisconsin–Madison · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here, we evaluated the expression of CYP24A1, a protein that inactivates vitamin D in tissues. CYP24A1 expression was increased in advanced-stage endometrial tumors compared to normal tissues. Similarly, endometrial cancer cells expressed higher levels of CYP24A1 than immortalized endometrial epithelial cells. RT-PCR and Western blotting were used to examine CYP24A1 mRNA and protein levels in endometrial cancer cells after 8, 24, 72, and 120 h of exposure to progesterone, progestin derivatives and calcitriol, either alone or in combination. Progestins inhibited calcitriol-induced expression of CYP24A1 and splice variant CYP24SV mRNA and protein in cancer cells. Furthermore, actinomycin D, but not cycloheximide, blocked calcitriol-induced CYP24A1 splicing. siRNA-induced knockdown of CYP24A1 expression sensitized endometrial cancer cells to calcitriol-induced growth inhibition. These data suggest that CYP24A1 overexpression reduces the antitumor effects of calcitriol in cancer cells and that progestins may be beneficial for maintaining calcitriol's anti-endometrial cancer activity.

Indexed as

AdultAgedCalcitriolCell Line, TumorCell ProliferationDrug SynergismEndometrial NeoplasmsFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedNeoplasm GradingProgesteroneVitamin D3 24-HydroxylaseCalcitriolCYP24A1 protein, humanProgesteroneVitamin D3 24-Hydroxylasecalcitriolcell proliferationchemopreventionprogesteronevitamin D receptor

Identifiers

PMID27769055
PMCPMC5363606
OpenAlexW2539421190

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.